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Purpose or Objective: Hyperthermia (raising the tumour 
temperature to 40-43°C) is an effective treatment in 
combination with radiotherapy for several tumour sites, 
including cervical cancer, which is mainly caused by infection 
with the Human Papillomavirus (HPV). The aim of our study is 
to improve treatment strategies for cervical carcinoma by 
(#1) unravelling mechanisms of hyperthermia induced 
radiosensitization, (#2) optimization of time interval between 
hyperthermia and radiotherapy and (#3) investigating the 
benefit of additional treatments. 
 
Material and Methods: HPV-positive cervical cell lines SiHa 
and HeLa were used. Cells were treated with (#1) 
hyperthermia alone (42˚C for 1h), (#2) hy perthermia and 
irradiation in different time intervals between the two 
therapies and (#3) hyperthermia and radiation with 
additional agents PARP1-inhibitor (i.e. a drug blocking a DNA 
repair protein) and cisplatin. Clonogenic survival assays and 
γH2AX stainings (a staining to visualize DNA double strand 
breaks) were carried out in order to determine the 
effectiveness of the (combined) treatments. Protein levels of 
p53 and DNA repair proteins were investigated using western 
blot. Apoptosis was measured in cell lines using the Nicoletti 
assay and cell cycle distribution was analyzed using the BrdU-
assay. 
 
Results: (#1) The high-risk HPV types 16 and 18 produce the 
oncoprotein, early protein 6 (E6), which binds to p53 before 
both proteins get degraded. Therefore, p53 cannot induce 
cell cycle block nor apoptosis, limiting the radiation effects. 
Hyperthermia increases the effectiveness by preventing the 
formation of the E6-p53 complex, rescuing p53 from 
degradation, resulting into functional p53 causing apoptosis 
and cell cycle arrest. (#2) Higher levels of p53 are present 
immediately after hyperthermia and remain up to four hours 
after treatment. The main therapy, radiotherapy or 
chemotherapy, should be applied within this time frame to 
yield a beneficial effect. (#3) Combination treatment of 
radiotherapy, hyperthermia, cisplatin and PARP1-inhibitors 
resulted in a lower survival fraction due to an increased 
number of DNA double strand breaks as compared to 
radiation alone. Cisplatin and PARP1-inhibition significantly 
enhanced the combined hyperthermia/radiation treatment. 
 
 
 
 
Conclusion: Our findings provide new insights for patients 
suffering from HPV-positive cervical cancer. Hyperthermic-
radiosensitization, makes radiotherapy significantly more 
effective by rescuing p53 from getting degraded. Adding 
PARP1-inhibitor or cisplatin further improves the 
effectiveness of hyperthermic-radiosensitization, which will 
increase clinical outcomes substantially.  
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Purpose or Objective: To theoretically evaluate therapeutic 
gain from radiation dose enhancement by gold nanoparticles 
(AuNP) based on their physical interaction with protons.  
 
Material and Methods: Nanoparticles range in size from 1 x 
10⁻⁹m to 100 x 10⁻⁹m, and exert their effect by either 
entering the cell, or by attaching to the cell membrane 
surface. Radiation enhancement by gold nanoparticles (AuNP) 
is based on the generation of much localized secondary 
radiation when irradiated. This results in a Dose Enhancment 
Factor (DEF) and has been well described for photon 
irradiation and is most pronounced with kilo voltage photons, 
but happens also with Mega Voltage (MeV). For protons the 
DEF obtained with metallic nanoparticles has recently been 
studied. We took the definition of DEF as being: DEF=( Dpure 
+ DGNP – Dwnp )/ Dpure , where Dpure is the dose deposited 
in pure water.  
 
Results: In vivo studies on tumors in mice have shown a 
considerable delay in tumor growth for mice receiving AuNPs 
with protons compared to protons alone. Protons have a high 
cross-section for gold over a large range of clinical energies, 
and the interaction produces Auger electrons with a very 
short range. The sphere of DEF around the AuNP is influenced 
by its size. For an AuNP of r = 22nm and 80 MeV protons the 
radius of the sphere of DEF is in the order of 18nm, with dose 
enhancement factors of up to 2 described. We obtained a 
value of 1.06 at 1 nm from a nanoparticle with radius 25 nm 
and taking Dpure as being: Dpure [Gy] ≈ 8.16 x Sw [ MeV x 
cm2/g ], where Sw is the stopping power of water. This small 
radius means that in order to be effective the AuNPs need to 
be in very close contact with the target. In the treatment of 
AVMs the prime target is the endothelial cell. Angiogenesis 
occurring in AVMs is driven by endothelial cells stimulated by 
vascular angiogenic factors binding on cell membrane 
receptors. AVM endothelial cells over express these receptors 
compared to their counterparts in normal brain vessels. IMC-
1121B, a human antibody to VEGFReceptor2, when linked 
with an AuNP has the potential to selectively increase the 
local AuNP concentration on the membrane of AVM 
endothelial cells. For conventional dose/fractionation 
schedules the radiobiological effects are governed by DNA 
damage in the cell nucleus. Membrane location could also be 
exploited because a cell membrane initiated effect is 
described, whereby activation of the acid 
sphingomyelinase/ceramide pathway occurs after doses >10 
Gy, leading to endothelial apoptosis. 
 
Conclusion: Successful AVM radiosurgery is amongst others 
dose dependent. Therapeutic gain in proton radiosurgery is 
possible with AuNP-VEGFR2ab located on the cell membrane, 
combined with doses > 10 Gy. This approach needs to be 
researched further, but offers the possibility for better 
obliteration rates and/or shorter latent intervals.  
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Purpose or Objective: Soft-tissue sarcomas (STS) are 
aggressive tumours with a poor prognosis and there is a major 
clinical need for novel strategies. Poly-ADP ribose polymerase 
(PARP)-1 promotes base excision repair and DNA strand break 
repair. Inhibitors of PARP (PARPi) have shown to enhance the 
cytotoxic effect of irradiation (IR), and evidences suggest 
that PARPi could be used to selectively kill cancers defective 
in DNA repair. Sarcomagenesis is linked to aberrant biological 
pathways and some STS have defect in DNA repair systems, so 
there is a rationale for using PARPi in STS. We investigated 
the effect of PARP inhibition on STS cell lines survival after IR 
and on radiation-induced DNA damage foci. 
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Material and Methods: Cell proliferation analysis was 
performed on human fibrosarcoma, liposarcoma, 
leiomyosarcoma and rhabdomyosarcoma cell lines with 
increasing doses of olaparib (0.25; 0.5; 1; 2; 4 μM) 3 h after 
cells seeding. The numbers of cells were assessed after 5 
days and results normalized to the untreated control. For 
clonogenic assays, fibrosarcoma, liposarcoma, 
leiomyosarcoma and rhabdomyosarcoma cells were irradiated 
with 2, 4 or 6 Gy, with or without olaparib (1 µM) iniparib (10 
µM) or veliparib (5μM) pre-treatment. The plating efficiency 
of the combined treatments were normalized to PARPi-
treated cells. The linear-quadratic survival expression was 
fitted to the data by nonlinear regression. The 
radiosensitization enhancement ratio for the PARPi at 50% 
survival (ER50) was as follows: ER50 = Dose at 50% survival 
without PARPi/Dose at 50% survival with PARPi. The impact 
of PARP inhibition on γ-H2Ax foci formation was evaluated in 
rhabdomyosarcoma cells treated with olaparib 1 μM after 48 
h, and irradiated at 4 Gy. Cells were probed with primary 
antibody to γ-H2AX. 
 
Results: Continuous treatment with olaparib for 5 days 
resulted in a dose-dependent inhibition of proliferation in all 
the STS cell lines. Significant radiosensitization was observed 
in all human STS cell lines using PARPi, with an ER50 ranging 
from 1.2 to 3.41. Rhabdomyosarcoma showed the greatest 
increase in radiosensitivity, with an ER50 of 3.41 with 
veliparib. Fibrosarcoma showed an ER50 of 2.29 with olaparib 
and 2.21 with veliparib. Leiomyosarcoma and liposarcoma 
showed similar radiation responses after PARP inhibition, 
with the higher radiosensitization in presence of veliparib 
(ER50 1.62 and 1.46, respectively). The combination of 
olaparib and radiation in rhabdomyosarcoma cells resulted in 
an increased number of γH2AX foci as compared to control 
and irradiation alone. 
 
Conclusion: We demonstrated that PARPi are potent 
radiosensitizers on human STS in vitro models. The different 
PARPi radiosensitizing effects observed in various cell lines 
may be explained by the presence of different genomic 
aberrations in DNA repair machinery in specific STS subtypes. 
These preliminary data encourage to further study 
association of PARPi with IR as a promising treatment for STS. 
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Purpose or Objective: Glioblastoma (GBM) is the most 
common primary brain tumor in adults. Despite intense 
treatment, including surgery and radiochemotherapy, 
prognosis is dismal with a median overall survival time of only 
15 months. The vascular endothelial growth factor-A (VEGF-
A) has been identified as one of the key regulators of 
neoangiogenesis in these highly vascularized tumors. 
Therefore, disruption of the VEGF-A signaling cascade by 
neutralizing VEGF-A and preventing ligation of its receptors 
appeared to be a promising approach for targeting 
neoangiogenesis. However, in recent phase III trials 
application of the VEGF-A blocking antibody bevacizumab in 
combination with radiochemotherapy failed to prolong 
overall survival in newly diagnosed GBM despite increasing 
progression-free survival and improving performance status. 
The aim of our study was to analyze the treatment effects of 
radiotherapy in combination with bevacizumab in a clinically 
relevant setting. Therefore, we established an orthotopic, 
syngeneic mouse glioblastoma model and subjected it to 
fractionated radiotherapy in combination with the 
bevacizumab mouse analogue G6-31. 
Material and Methods: GL261 mouse GBM cells were 
stereotactically transplanted into the frontal lobe of C57/BL6 
mice and tumors were allowed to grow for one week. 
Radiation therapy was performed with a Small Animal 
Radiation Research Platform (SARRP, Xstrahl) which 
incorporates contrast agent-CT (CA-CT)-based imaging 
followed by high precision radiation delivery. Fractionated 
irradiation with daily doses of 2 Gy up to a cumulative dose 
of 20 Gy was administered with or without accompanying 
VEGF-A blockade by the mouse bevacizumab analogue G6-31. 
Overall survival and tumor size were monitored, histological 
analyses, and transcriptomic profiling of tumor and normal 
tissue are currently being performed. 
 
Results: Stereotactic implantation of GBM was successfully 
accomplished, fractionated irradiation was implemented by 
CA-CT-based image guidance, and tumor growth was 
successfully monitored by serial CA-CT scans. The single 
agent treatments led to a significant delay in tumor growth 
and prolongation of survival as compared to the sham-treated 
controls. Importantly, the strongest therapeutic effects were 
observed with the combined treatment. Histological details, 
including vessel density and structure, as well as markers of 
cell death induction, and transcriptomic profiling of tumor 
and normal tissue are currently under investigation. 
 
Conclusion: This pilot study shows that syngeneic, orthotopic 
glioblastoma transplants combined with stereotactically 
delivered radiotherapy are feasible and clinically relevant in 
vivo models for evaluating the therapeutic efficacy of 
multimodal treatment approaches based on fractionated 
irradiation. 
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Purpose or Objective: Injected gold nano particles(GNPs) to 
a body for dose enhancement are known to form cluster 
morphology. We investigated the dependence of dose 
enhancement on the morphology characteristic with an 
approximated morphology model by using Monte Carlo 
simulations. 
 
Material and Methods: For MC simulation, TOPAS v.b-12 was 
used. GNPs of 50 and 100 nm diameter were tested. GNP 
cluster morphology was approximated as a body center cubic 
by placing 8 GNPs at the corner and one at the centered of a 
2 × 2 × 2 μm³, 1 × 1 × 1 μm³, 0.5 × 0.5 × 0.5 μm³, or 0.25 × 
0.25 × 0.25 μm³ (for 100 nm GNP) or 0.18 × 0.18 × 0.18 μm³ 
(for 50 nm GNP) cube located in a 4 × 4 × 4 μm³ water filled 
cube phantom. 4 μm × 4 μm square shaped beams of 
spectrum-energetic 50, 100 kVp photons and 70, 170 MeV 
protons were irradiated to the water filled cube phantom 
with GNPs in it. We computed the distribution of secondary 
electrons as a function of distance from the surface of the 
GNP at the cube center and calculated the ratio (SER) 
together with dose enhancement ratio (DER) for 4 different 
cubes geometries. For scoring particles,10 nm width of 
concentric shell shaped detector was constructed up to 100 
nm from the center point of the cube. 10E8 histories of 
protons and 2 × 10E10 histories of photons were used for 
simulation. All counted values at each detector were summed 
to obtain the total dose and secondary electrons in a sphere 
of 100 nm radius and were normalized to 2 × 2 × 2 μm³ cube 
morphology. 
